#1 Clinical Trials Search in Europe

SAR445399

Clinical trials are investigating SAR445399 in adults with moderate to severe hidradenitis suppurativa. These studies aim to evaluate efficacy and safety, including different doses, in people living with this long-term skin condition.

Table of contents

Trial overview

This article covers one interventional study of SAR445399 in adults with moderate to severe hidradenitis suppurativa.[1] The study is listed as authorised and is a Phase 2 trial with a planned enrollment of 206 participants.[1]

Condition and target population

The trial is studying hidradenitis suppurativa (HS), a long-term skin condition, in adults who have moderate to severe disease.[1] This means the study is focused on people whose symptoms are not mild and who may need more active treatment research options.[1]

Study design and phase

The available data describe SAR445399 as part of a Phase 2 study.[1] Phase 2 trials are used to learn more about whether a treatment may work and to keep checking safety in a defined patient group.[1]

The study summary says it is evaluating different doses of SAR445399.[1] In simple terms, the researchers are comparing amounts of the study treatment to see how well they may help people with this condition.[1]

What is being measured

The main goal of the study is to evaluate efficacy, which means how well the treatment works for the target condition.[1] The trial also aims to assess safety, meaning whether the treatment can be used without causing unacceptable harm in the study setting.[1]

Because the brief summary specifically mentions efficacy of different doses, the study is likely focused on whether one dose works better than another for people with hidradenitis suppurativa.[1]

Who may join the study

The trial data state that the study is for adult participants with moderate to severe hidradenitis suppurativa.[1] No other eligibility details are provided in the source data, so the full set of entry rules cannot be confirmed here.[1]

Why this trial matters

Hidradenitis suppurativa can be difficult to manage when it is moderate to severe, so studies like this one are important for finding better treatment options.[1] This trial may help show whether SAR445399 is worth studying further in this patient group.[1]

Trial ID Phase Condition studied Status Enrollment
2025-522695-83-00 Phase 2 Moderate to severe hidradenitis suppurativa Authorised 206

FAQ

  • What is SAR445399 being studied for? SAR445399 is being studied in adults with moderate to severe hidradenitis suppurativa. The trial is looking at whether different doses can help and whether the treatment is safe.
  • Who can take part in the trial? The study is for adult participants with moderate to severe hidradenitis suppurativa. The trial data do not give more detail about other eligibility rules.
  • What phase is the SAR445399 trial? The trial is a Phase 2 study. Phase 2 trials usually look more closely at whether a treatment works and continue to check safety.
  • How many people are planned to join? The planned enrollment is 206 participants. Enrollment means the number of people the study aims to include.
  • What is the main goal of the study? The main goal is to evaluate the efficacy of different doses of SAR445399. Efficacy means how well the study treatment works in the target condition.

Ongoing Clinical Trials on SAR445399

Unfortunately, we did not find any clinical trials matching the selected criteria. Try changing the filter settings or broadening the search criteria to see more available research participation opportunities.

Glossary

  • Clinical trial: A research study in people that tests whether a treatment is safe and whether it works.
  • Interventional study: A study where participants receive a treatment or procedure so researchers can measure its effects.
  • Phase 2: A mid-stage clinical trial that mainly looks at whether a treatment works and continues safety checks.
  • Hidradenitis suppurativa (HS): A long-term skin condition that can cause painful lumps and swelling, often in areas where skin rubs together.
  • Moderate to severe: A description of how serious a condition is. Moderate to severe means the disease is more than mild.
  • Efficacy: How well a treatment works in a study.
  • Safety: Information about whether a treatment causes harmful effects.
  • Dose: The amount of a treatment given in a study.
  • Adult participants: People who are 18 years old or older and are taking part in the study.
  • Enrollment: The number of people a study plans to include.

References

  1. https://clinicaltrials.gov/study/2025-522695-83-00